Gold prices bounce off 3-week lows; demand likely longer term
SUMMIT, N.J. - Kenvue Inc. (NYSE:KVUE), a leading consumer health company with a market capitalization of $44.34 billion and impressive gross profit margins of 58%, announced the appointment of Amit Banati as its new Chief Financial Officer, effective May 12, 2025. According to InvestingPro data, the company has maintained strong financial health with annual revenues of $15.46 billion. Banati, who brings over three decades of experience in finance and operations within the consumer products sector, will take over from Paul Ruh, ensuring a seamless transition with Ruh’s assistance during the handover period.
Banati’s extensive background includes significant roles at Kellanova, Kraft Foods, Cadbury Schweppes, and Procter & Gamble, with a strong track record in leading profitable growth and business transformations, especially in international markets such as Asia Pacific, the Middle East, India, and Africa.
Thibaut Mongon, CEO of Kenvue, expressed confidence in Banati’s capabilities, highlighting his "world-class" executive experience and his fit for leading the company’s finance and strategy organizations into the future. Banati is set to focus on supporting revenue growth, improving margin and cost profiles, strengthening cash flow, and fostering greater agility within the company.
Banati shared his enthusiasm for joining Kenvue and his commitment to leveraging the company’s global scale and iconic consumer health brands to drive shareholder value. His approach will include enhancing data management, resource allocation, integrated business planning, and financial forecasting.
The announcement comes as Kenvue continues to establish itself as an independent entity, following one of the largest separations in public company history. The outgoing CFO, Paul Ruh, was commended for his contributions to the company’s transformation and P&L structure, which have set the stage for future growth.
In tandem with the CFO announcement, Kenvue also released its fiscal first-quarter financial results for the period ending March 30, 2025, further details of which can be accessed through the company’s investor relations website.
This leadership change is part of Kenvue’s ongoing strategic initiatives aimed at accelerating profitable growth and enhancing shareholder value. The information is based on a press release statement from Kenvue Inc.
In other recent news, Kenvue Inc. has been the subject of several analyst reports and strategic developments. Jefferies has raised its price target for Kenvue to $27.00, maintaining a Buy rating, highlighting the company’s increased reinvestment rate and strategic shift towards growth. Piper Sandler also increased their target to $27.00, reiterating an Overweight rating, noting Kenvue’s positive outlook for the second half of the year and their progress in the Skin Health & Beauty segment. Meanwhile, Redburn-Atlantic initiated coverage with a Neutral rating and a $23.50 target, expressing concerns over Kenvue’s organic sales growth and EPS projections for 2025. Evercore ISI assigned an "In Line" rating with a $25.00 target, pointing out the challenges in revitalizing the Skin Health & Beauty segment despite increased marketing efforts.
Additionally, Kenvue announced the appointment of three new independent directors as part of a cooperation agreement with Starboard Value LP. This board expansion aims to enhance Kenvue’s strategic focus on sustainable growth and shareholder value. The new directors bring expertise in brand building and global consumer health, which aligns with Kenvue’s market leadership goals. These developments come as Kenvue continues to navigate its post-spinoff landscape, aiming to optimize its portfolio and improve key business segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.